

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 10, 2003, 21:31:17 ; Search time 156.822 Seconds
(without alignments)
488.248 Million cell updates/sec

Title: US-09-913-524-32
Perfect score: 34
Sequence: 1 aggcctcgaggagaaacgactccatcgaact 34

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002.*

	1: /SID52/qcqdta/geneseq/geneseq-emb1/NA1980.DAT.*	2: /SID52/qcqdta/geneseq/geneseq-emb1/NA1981.DAT.*	3: /SID52/qcqdta/geneseq/geneseq-emb1/NA1982.DAT.*	4: /SID52/qcqdta/geneseq/geneseq-emb1/NA1983.DAT.*	5: /SID52/qcqdta/geneseq/geneseq-emb1/NA1984.DAT.*	6: /SID52/qcqdta/geneseq/geneseq-emb1/NA1985.DAT.*	7: /SID52/qcqdta/geneseq/geneseq-emb1/NA1986.DAT.*	8: /SID52/qcqdta/geneseq/geneseq-emb1/NA1987.DAT.*	9: /SID52/qcqdta/geneseq/geneseq-emb1/NA1988.DAT.*	10: /SID52/qcqdta/geneseq/geneseq-emb1/NA1989.DAT.*	11: /SID52/qcqdta/geneseq/geneseq-emb1/NA1990.DAT.*	12: /SID52/qcqdta/geneseq/geneseq-emb1/NA1991.DAT.*	13: /SID52/qcqdta/geneseq/geneseq-emb1/NA1992.DAT.*	14: /SID52/qcqdta/geneseq/geneseq-emb1/NA1993.DAT.*	15: /SID52/qcqdta/geneseq/geneseq-emb1/NA1994.DAT.*	16: /SID52/qcqdta/geneseq/geneseq-emb1/NA1995.DAT.*	17: /SID52/qcqdta/geneseq/geneseq-emb1/NA1996.DAT.*	18: /SID52/qcqdta/geneseq/geneseq-emb1/NA1997.DAT.*	19: /SID52/qcqdta/geneseq/geneseq-emb1/NA1998.DAT.*	20: /SID52/qcqdta/geneseq/geneseq-emb1/NA1999.DAT.*	21: /SID52/qcqdta/geneseq/geneseq-emb1/NA2000.DAT.*	22: /SID52/qcqdta/geneseq/geneseq-emb1/NA2001A.DAT.*	23: /SID52/qcqdta/geneseq/geneseq-emb1/NA2001B.DAT.*	24: /SID52/qcqdta/geneseq/geneseq-emb1/NA2002.DAT.*
Pred. No.	is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.																							

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	34	100.0	405	22	AAF84904
2	34	100.0	1134	7	AAN60428
3	34	100.0	1237	8	AAN70314
4	34	100.0	1338	9	AAN80040
5	34	100.0	3422	22	AA103358
6	34	100.0	3422	22	AA103360
7	34	100.0	3422	22	AA528909
8	34	100.0	3422	22	AA528911
9	26	76.5	1182	7	AAN60426

10	24.4	71.8	1343	8	AAN70310	Sequence encoding
11	20.8	61.2	5172	23	ABL12657	Drosophila melanog
12	20.8	61.2	6410	23	ABL12656	Drosophila melanog
13	20.4	60.0	1087	22	AAH14269	Human cDNA sequenc
14	20.4	60.0	1125	21	AAF16239	Human prostate can
15	20.4	60.0	1183	21	AA298235	Human signal pepti
16	20.4	60.0	2297	22	AAH98586	Human EST-derived
17	20.4	60.0	3210	23	ABL12861	Drosophila melanog
18	20.4	60.0	5981	23	ABL12860	Drosophila melanog
19	20.4	60.0	6109	23	AAH78667	Murine Col5a3 cDNA
20	20.2	59.4	1812	22	AAH08562	Human partial card
21	20.2	59.4	2127	19	AAV23246	Human adenylyl cycl
22	20.2	59.4	3192	22	AA521281	Human cDNA sequenc
23	20.2	59.4	3549	22	AAH08563	Human cardiac aden
24	20.2	59.4	3552	22	AAH08567	Human cardiac aden
25	20.2	59.4	4046	14	AAQ42523	Cardiac adenylyl c
26	20.2	59.4	4131	21	AA53923	Type VI adenylyl c
27	20.2	59.4	4942	20	AAH00461	Human type VI aden
28	20.2	59.4	5145	22	AAH06014	Human neuronal apo
29	19.6	57.6	397	24	ABN17793	Human ORFX polynuc
30	19.6	57.6	1419	23	AA573088	DNA encoding novel
31	19.6	57.6	22085	23	AAH19932	Drosophila melanog
32	19.6	57.6	37687	23	ABL29366	Drosophila melanog
33	19.4	57.1	1484	23	AA587966	DNA encoding novel
34	19.4	57.1	47981	22	AAF30757	Micromonospora neg
35	19.2	56.5	243	22	AAK55450	Human immune/haema
36	19.2	56.5	490	22	AAK66017	Human immune/haema
37	19.2	56.5	492	23	ABL25897	Drosophila melanog
38	19.2	56.5	681	23	ABL21909	Drosophila melanog
39	19.2	56.5	703	24	AA562745	cDNA sequence #532
40	19.2	56.5	1139	22	AAF27731	Human transport pr
41	19.2	56.5	2112	23	ABL25896	Drosophila melanog
42	19.2	56.5	2777	23	ABL21908	Drosophila melanog
43	19.2	56.5	3487	23	ABL04548	Drosophila melanog
44	19.2	56.5	4035	23	ABL04815	Drosophila melanog
45	19.2	56.5	4736	22	AA527831	DNA encoding novel

ALIGNMENTS

RESULT 1
AAF84904
ID AAF84904 standard; DNA; 405 BP.
XX
XX AAF84904;
XX
XX 09-JUL-2001 (first entry)
XX
XX Nucleotide sequence of an alphaC fragment of human inhibin.
DE
XX AlphaC portion; inhibin; alpha-subunit; glycoprotein;
KW follicle stimulating hormone; FSH; cancer; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH CDS 1..405
FT /*tag= a
FT /product= "alphaC fragment of human inhibin"
XX
XX WO200129079-A1.
XX
XX 26-APR-2001.
XX
XX 18-OCT-2000; 2000WO-AU01258.
XX
XX 18-OCT-1999; 99AU-0003485.
XX
XX 03-AUG-2000; 2000AU-0009162.
XX
XX (PRIN-) PRINCE HENRY'S INST MEDICAL RES.
XX
XX (GROO/) GROOME N P.

PI Forage R, Stewart A, Robertson D, Dekretser DM;
XX WPI; 1986-291647/44.
XX P-PSDB; AAP60519.
XX
XX New polynucleotide sequences and recombinant DNA - encoding
PT inhibit and synthetic peptides useful for affecting gonadal
PT function
XX
XX Claim 8; Fig 7; 71pp; English.
XX
XX DNA encoding inhibit and inhibit or part, analogues, homologues or
CC precursors thereof when produced by recombinant techniques are also
CC claimed, as well as pharmaceutical compositions thereof. These may
CC be used as an inhibit agonist, antagonist or for eliciting an
CC antigenic response to affect gonadal function or reproductive
CC physiology.
XX
XX Sequence 1134 BP; 182 A; 400 C; 322 G; 230 T; 0 other;
SQ
XX
XX Query Match 100.0%; Score 34; DH 7; Length 1134;
XX Best Local Similarity 100.0%; Pred. No. 0.00061;
XX Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps
XX
XX QY 1 AGCGCTCCGGAGAACGGCTGCTATGCCAACT 34
XX ||||||||||||||||||||||||||||
XX Db 758 AGCGCTCCGGAGAACGGCTGCTATGCCAACT 791
XX
XX RESULT 3
XX AAN70314
XX ID AAN70314 standard; cDNA; 1247 BP.
XX
XX AC AAN70314;
XX
XX DT 09-APR-1991 (first entry)
XX
XX DE Sequence encoding human inhibit alpha-chain precursor.
XX
XX KW fertility control; contraception; hormone; spermatogenesis; ss.
XX
XX CS Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 3..50
XX /*taq= a
XX /product=signal sequence
XX 51..653
XX /*taq= b
XX /product=pro region
XX mat_peptide 654..1058
XX /*tag= c
XX poly_A signal 1216..1221
XX /*tag= d
XX
XX EP222491-A.
XX
XX PN 20-MAY-1987.
XX
XX XX 02-OCT-1986; 86EP-0307586.
XX
XX PF 12-SEP-1986; 86US-0906729.
XX PR 03-OCT-1985; 85US-0783910.
XX PR 10-FEB-1986; 86US-0827710.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Mason AJ, Seeburg PH;
XX
XX WPI; 1987-137512/20.
XX PR P-PSDB; AAP70202.
XX
XX Recombinant human or porcine inhibit or active used for

PT modulating clinical condition or reproductive physiology of
PT animals.
XX
XX Disclosure; Fig 6A; 48pp; English.
XX
CC A compsn. comprising human or porcine inhibin which is completely
CC free of unidentified or porcine proteins is claimed. Also claimed
CC are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
CC chain. Sequencing of inhibin-encoding cDNA has led to the
CC identification of prodomain regions located N-terminal to the
CC mature inhibin chains that represent coordinately expressed
CC biologically active polypeptides. The prodomain regions or
CC prodomain immunogens are useful in monitoring preproinhibin
CC processing in transformant cell culture or in experiments directed
CC at modulating the clinical condn. or reproductive physiology of
XX animals.
XX
SQ Sequence 1237 BP; 210 A; 431 C; 346 G; 250 T; 0 other;
Query Match 100.0%; Score 34; DB 8; Length 1237;
Best Local Similarity 100.0%; Pred. No. 0.00061;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGCTCGGAGAACCGCTGCCCATGCCAACT 34
|||||
DB 708 AGGCTCGGAGAACCGCTGCCCATGCCAACT 741
RESULT 4
AAN80040
ID AAN80040 standard; DNA; 1338 BP.
XX
AC AAN80040;
XX
XX 28-JAN-1993 (first entry)
XX
DE Sequence encoding the 18K alpha-chain of a protein exhibiting
DE inhibin activity and its N-terminal sequence.
XX
XX Fertility control; inhibin; follicle stimulating hormone; inhibitor;
KW gonadotropin; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FT CDS 145..840
FT /*tag- a
FT /product= N-terminal sequence
FT CDS 841..1245
FT /*tag- b
FT /product= 18 K chain
FT /note= "claimed"
XX
XX US4737578-A.
XX
XX 12-APR-1988.
XX
XX 07-APR-1986; 86US-0848924.
XX
XX 07-APR-1986; 86US-0848924.
XX 10-FEB-1986; 86US-0828435.
XX
XX (SALK) SALK INS! FOR BIOL. STUD.
XX
XX Evans RM, Rosenfeld MC, Cerelli G, Mayo KE, Spiess J;
PI Rivier JEF, Vale WW;
XX WPI: 1988-119128/17.
DR P-PSDB; AAP8167.
XX
XX New proteins with inhibin activity - esp. useful for controlling
PT fertility in males
XX

PS Disclosure; Table 1, page 6-7; 6pp; English.
XX
CC The inventors claim 2 proteins - A and B - each of which has a
CC molecular weight of about 32k and is comprised of an alpha (18k) and
CC a beta (14k) chain of human inhibin. The alpha chain is AAP80018.
CC The beta chain is either AAP80019 or AAP80020. Proteins A and B are
CC useful for regulating fertility of mammals. Each 32k protein
CC exhibits inhibin activity in basal secretion of PHS but not
CC inhibiting basal secretion of luteinizing hormone (LH).
XX
SQ Sequence 1338 BP; 232 A; 433 C; 417 G; 256 T; 0 other;
Query Match 100.0%; Score 34; DB 9; Length 1338;
Best Local Similarity 100.0%; Pred. No. 0.00062;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGGCTCGGAGAACCGCTGCCCATGCCAACT 34
|||||
DB 895 AGGCTCGGAGAACCGCTGCCCATGCCAACT 928
RESULT 5
AAL03358/C
ID AAL03358 standard; DNA; 1422 BP.
XX
AC AAL03358;
XX
XX 21-NOV-2001 (first entry)
XX
XX Human reproductive system related antigen DNA SEQ ID NO: 6046.
DE
XX Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX WO200155320-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01319.
XX
XX 31-JAN-2000; 2000US-0179065.
XX 04-FEB-2000; 2000US-0180628.
XX 24-FEB-2000; 2000US-0184664.
XX 02-MAR-2000; 2000US-0186350.
XX 16-MAR-2000; 2000US-0189874.
XX 17-MAR-2000; 2000US-0190076.
XX 18-APR-2000; 2000US-0194124.
XX 19-MAY-2000; 2000US-0205515.
XX 07-JUN-2000; 2000US-0209467.
XX 28-JUN-2000; 2000US-0214886.
XX 30-JUN-2000; 2000US-0215135.
XX 07-JUL-2000; 2000US-0216647.
XX 07-JUL-2000; 2000US-0216880.
XX 11-JUL-2000; 2000US-0217487.
XX 11-JUL-2000; 2000US-0217496.
XX 14-JUL-2000; 2000US-0218290.
XX 26-JUL-2000; 2000US-0220963.
XX 26-JUL-2000; 2000US-0220964.
XX 14-AUG-2000; 2000US-0224518.
XX 14-AUG-2000; 2000US-0224519.
XX 14-AUG-2000; 2000US-0225213.
XX 14-AUG-2000; 2000US-0225214.
XX 14-AUG-2000; 2000US-0225266.
XX 14-AUG-2000; 2000US-0225267.
XX 14-AUG-2000; 2000US-0225268.
XX 14-AUG-2000; 2000US-0225270.
XX 14-AUG-2000; 2000US-0225447.
XX 14-AUG-2000; 2000US-0225757.
XX 14-AUG-2000; 2000US-0225758.
XX 14-AUG-2000; 2000US-0225759.
XX 18-AUG-2000; 2000US-0226279.

PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232359.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236569.
PR 29-SEP-2000; 2000US-0236570.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.

PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251858.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259578.
XX
PA {HUMA-} HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
PI
XX WPI; 2001-465570/50.
DR
XX
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen -
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 6046; 1297pp ; Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 3422 BP; 806 A; 898 C; 462 G; 756 T; 0 other;

Query Match 100.0%; Score 34; DH 22; Length 3422;
Best Local Similarity 100.0%; Pred. No. 0.00065;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGCCTCGGAGAACCGGCTGCATGCCAACT 34
|||||
Db 538 AGGCCTCGGAGAACCGGCTGCATGCCAACT 505

RESULT 6
AAL03360/c
ID AAL03360 standard; DNA; 3422 BP.
XX
AC AAL03360;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 6048.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ds.

XX
OS
XX Homo sapiens.
PN W0200155320-A2.
XX
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216847.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 12-SEP-2000; 2000US-0232081.
PR 14-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 25-SEP-2000; 2000US-0234999.

PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237049.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249246.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 06-DEC-2000; 2000US-0256719.
PR 08-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
 XX Rosen CA, Barash SC, Ruben SM;
 XX WPI; 2001-465570/50.
 XX Isolated nucleic acid molecule encoding a reproductive system antigen
 PT is used in preventing, treating or ameliorating a medical condition -
 PT Disclosure; SEQ ID NO 6048; 1297bp + Sequence Listing: English.
 XX The present invention provides the protein and coding sequences of a
 CC number of human reproductive system related antigens. These can be used
 CC in the prevention and treatment of reproductive system disorders,
 CC including cancer. The present sequence is a genomic sequence encoding a
 CC protein of the invention.
 XX
 SQ Sequence 3422 BP; 806 A; 898 C; 962 G; 756 T; 0 other;
 Query Match 100.0%; Score 34; DB 22; Length 3422;
 Best Local Similarity 100.0%; Pred. No. 0.00065;
 Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGGCTCCGGAGGACCGCTGCCATGCCAACT 34
 ||||||||||||||||||||||||||||||||||
 Db 538 AGGCTCCGGAGGACCGCTGCCATGCCAACT 505
 RESULT 7
 AAS28909/c
 ID AAS28909 standard; DNA: 3422 BP.
 XX
 AC AAS28909;
 XX
 DT 07-NOV-2001 (first entry)
 XX
 DE Human immunoglobulin encoding genomic DNA SEQ ID No 271.
 XX
 KW Immunoglobulin; signal transduction pathway protein; cancer; ds;
 KW antisense therapy; gene therapy; neurological disorder; renal disorder;
 KW cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
 KW reproductive disorder; immune system disorder; proliferative disorder;
 KW muscular disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200155315-A2.
 XX
 PD 02-AUG-2001.
 XX
 PF 17-JAN-2001; 2001WO-US01326.
 XX
 PR 31-JAN-2000; 2000US-0179065.
 PR 04-FEB-2000; 2000US-0180528.
 PR 24-FEB-2000; 2000US-0184664.
 PR 02-MAR-2000; 2000US-0186350.
 PR 16-MAR-2000; 2000US-0189874.
 PR 17-MAR-2000; 2000US-0190076.
 PR 18-APR-2000; 2000US-0198123.
 PR 19-MAY-2000; 2000US-0205515.
 PR 07-JUN-2000; 2000US-0209467.
 PR 28-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0216680.
 PR 11-JUL-2000; 2000US-0217487.
 PR 11-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220963.
 PR 26-JUL-2000; 2000US-0220964.
 PR 14-AUG-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226868.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 08-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 12-SEP-2000; 2000US-0232081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 01-NOV-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244517.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.

PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234397.
PR 25-SEP-2000; 2000US-0234398.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.

PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX (HUMA-) HUMAN GENOME SCI INC.
PA Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-457725/49.
XX Isolated novel immunoglobulin polypeptide for monitoring the presence
PT and progression of diseases and for diagnosis -
XX Claim 1; SEQ ID No 273; 551pp; English.
XX Sequences AAS28878-AAS28926 represent genomic DNA molecules which encode
CC the immunoglobulin polypeptides of the invention. The polynucleotides and
CC polypeptides can be used to diagnose a pathological condition or a
CC susceptibility to a pathological condition in a subject by determining
CC the presence or absence of a mutation in a DNA sequence or determining
CC the presence or amount of expression of the protein. Alternatively the
CC identification of a binding partner to a sequence allows determination of
CC changes in protein activity. The sequences can be used as research tools
CC for receptors or other signal transduction pathway proteins that interact
CC with the polypeptides of the invention and can be used to treat, prevent
CC or diagnose various types of disorders such as neurological disorders,
CC cardiovascular disorders, gastrointestinal disorders, reproductive
CC disorders, immune system disorders, renal disorders, muscular disorders,
CC pulmonary disorders, proliferative disorders and cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 3422 BP; 756 A; 962 C; 898 G; 806 T; 0 other;
SQ
Query Match 100.0%; Score 34; DB 22; Length 3422;
Best Local Similarity 100.0%; Pred. No. 0.00065;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGGCTTCGGAGGACGGCTGCCAIGCCAAC 34
Db 2885 AGGCTTCGGAGGACGGCTGCCAIGCCAAC 2918
RESULT 9
AAN60426
ID AAN60426 standard; cDNA; 1182 BP.
XX
AC AAN60426;
XX
DT 26-JUN-1991 (first entry)
XX


```

DE XX Sequence encoding bovine inhibin A subunit.
KW XX Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX OS Bos taurus.
XX FH Key Location/Qualifiers
XX FT CDS 61..240
XX FT /*tag= a
XX FT mat_peptide 241..1143
XX FT /*tag= b
XX PN W08606076-A.
XX PD 23-OCT-1986.
XX PF 14-APR-1986; 86WO-AU00097.
XX PR 20-DEC-1985; 85AU-0003961.
XX PR 18-APR-1985; 85AU-000194.
XX PR 06-SEP-1985; 85AU-0002320.
XX PR 29-OCT-1985; 85AU-0003157.
XX PR 19-DEC-1985; 85AU-0003960.
XX PR 01-JAN-1986; 86AU-0059039.
XX PR 02-APR-1987; 87AU-0071015.
XX PR 05-MAY-1986; 86CN-0103459.
XX PA (BIOT-) BIOTECHN AUSTR PTY.
XX PA (MON-) MONASH UNIV.
XX PA (HENR-) PRICE HENRY'S HOSPITAL.
XX PA (SVIN-) ST VINCENTS'S INST MED RE.
XX PI Forage R, Stewart A, Robertson D, Dekretser DM;
XX WPI; 1986-291647/44.
XX P-PSDB; AAP60517.
XX PT New polynucleotide sequences and recombinant DNA - encoding
XX PT inhibin and synthetic peptides useful for affecting gonadal
XX PT function
XX PS Claim 8; Fig 5; 71pp; English.
XX CC DNA encoding inhibin and inhibin or part, analogues, homologues or
XX CC precursors thereof when produced by recombinant techniques are also
XX CC claimed, as well as pharmaceutical compositions thereof. These may
XX CC be used as an inhibin agonist, antagonist or for eliciting an
XX CC antigenic response to affect gonadal function or reproductive
XX CC physiology.
XX SQ Sequence 1182 BP; 173 A; 414 C; 363 G; 232 T; 0 other;

Query Match 76.5%; Score 26; DB 7; Length 1182;
Best Local Similarity 85.3%; Pred. No. 0.79;
Matches 29; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 AGGCGCTCGGAGGAGGCGCTGCCATGCCAACT 34
DB 793 AGGCGTCAGAGGAGGCGCGCGCCCGCACT 836

RESULT 10
AAN70310
ID AAN70310 standard; cDNA; 1343 BP.
XX AC AAN70310;
XX DT 09-APR-1991 (first entry)
XX DE Sequence encoding porcine inhibin alpha-chain precursor.
XX KW Fertility control; contraception; hormone; spermatogenesis; ss.
XX PN

```

```

OS Sus scrofa domestica.
XX FH Key Location/Qualifiers
XX FT CDS 72..761
XX FT /*tag= a
XX FT /product=hydrophobic signal sequence a pro-region
XX FT mat_peptide 762..1166
XX FT /*tag= b
XX FT polyA_signal 1300..1305
XX FT /*tag= c
XX PN EP222491-A.
XX PD 20-MAY-1987.
XX PF 02-OCT-1986; 86EP-0307586.
XX PR 12-SEP-1986; 86US-0906729.
XX PR 03-OCT-1985; 85US-0783910.
XX PR 10-FEB-1986; 86US-0827710.
XX PA (GETH ) GENENTECH INC.
XX PI Mason AJ, Seeburg PH;
XX WPI; 1987-137512/20.
XX P-PSDB; AAP70199.
XX PT Recombinant human or porcine inhibin or activin - used for
XX PT modulating clinical condition or reproductive physiology of
XX PT animals.
XX PS Disclosure; Fig 1B; 48pp; English.
XX CC A compsn. comprising human or porcine inhibin which is completely
XX CC free of unidentified or porcine proteins is claimed. Also claimed
XX CC are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
XX CC chain. Sequencing of inhibin-encoding cDNA has led to the
XX CC identification of prodomain regions located N-terminal to the
XX CC mature inhibin chains that represent coordinately expressed
XX CC biologically active polypeptides. The prodomain regions or
XX CC prodomain immunogens are useful in monitoring preproinhibin
XX CC processing in transformant cell culture or in experiments directed
XX CC at modulating the clinical condn. or reproductive physiology of
XX CC animals.
XX SQ Sequence 1343 BP; 196 A; 472 C; 477 G; 258 T; 0 other;

Query Match 71.8%; Score 24.4; DB 8; Length 1343;
Best Local Similarity 82.4%; Pred. No. 3.3;
Matches 28; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 AGGCGCTCGGAGGAGGCGCTGCCATGCCAACT 34
DB 816 AGGCGCGCGGAGGAGGCGCTGTGTCACGCCGACT 849

RESULT 11
ABL12657
ID ABL12657 standard; cDNA; 5172 BP.
XX AC ABL12657;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster expressed polynucleotide SEQ ID NO 32453.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical; gene; ss.
XX OS Drosophila melanogaster.
XX PN W0200171042-A2.

```

XX PD 27-SEP-2001.
 XX XX
 XX 23-MAR-2001; 2001WO-US09231.
 XX PR 23-MAR-2000; 2000US-191637P.
 XX PR 11-JUL-2000; 2000US-0614150.
 XX PA (PEKE) PE CORP NY.
 XX PI Venter JC, Adams M, Li PWD, Myers EW;
 XX WP1: 2001-656860/75.
 XX DR P-PSDB; ABB68554.
 XX PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX PS Claim 1; SEQ ID NO 32453; 21pp + Sequence Listing; English.
 XX CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins
 CC (ABB57737-ABB72072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 XX SQ Sequence 5172 BP; 1286 A; 1567 C; 1489 G; 830 T; 0 other;
 Query Match 61.2%; Score 20.8; DB 23; Length 5172;
 Best Local Similarity 78.1%; Pred. No. 90;
 Matches 25; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 QY 1 AGCCCTCCGGAGGAACCGCTGCCCATGCCAA 32
 Db 2477 AAGCCGCGGTGGAAACCGCTGCCCATGCCAA 3008
 RESULT 12
 ABL12656/c
 ID ABL12656 standard; cDNA; 6410 BP.
 XX AC ABL12656;
 XX DT 26-MAR-2002 (first entry)
 XX DE Drosophila melanogaster expressed polynucleotide SEQ ID NO 32450.
 XX KW Drosophila; developmental biology; cell signalling; insecticide;
 XX KW pharmaceutical; gene; ss.
 XX OS Drosophila melanogaster.
 XX PA (PEKE) PE CORP NY.
 XX PI Venter JC, Adams M, Li PWD, Myers EW;
 XX WP1: 2001-656860/75.
 XX DR

P-PSDB; ABB68553.
 XX XX
 XX New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX PS Claim 1; SEQ ID NO 32450; 21pp + Sequence Listing; English.
 XX CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins
 CC (ABB57737-ABB72072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 XX SQ Sequence 6410 BP; 1179 A; 1787 C; 1832 G; 1612 T; 0 other;
 Query Match 61.2%; Score 20.8; DB 23; Length 6410;
 Best Local Similarity 78.1%; Pred. No. 91;
 Matches 25; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 QY 1 AGCCCTCCGGAGGAACCGCTGCCCATGCCAA 32
 Db 3335 AAGCCGCGGTGGAAACCGCTGCCCATGCCAA 3304
 RESULT 13
 ABL14269
 ID ABL14269 standard; cDNA; 1087 BP.
 XX AC ABL14269;
 XX DT 26-JUN-2001 (first entry)
 XX DE Human cDNA sequence SEQ ID NO:11590.
 XX KW Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
 XX OS Homo sapiens.
 XX PN EP1074617-A2.
 XX PD 07-FEB-2001.
 XX PF 28-JUL-2000; 2000EP-0116126.
 XX PR 29-JUL-1999; 99JP-0248036.
 XX PR 27-AUG-1999; 99JP-0300253.
 XX PR 11-JAN-2000; 2000JP-0118776.
 XX PR 02-MAY-2000; 2000JP-0183767.
 XX PR 09-JUN-2000; 2000JP-0241899.
 XX PA (HELI-) HELIX RES INST.
 XX PI Ota T, Isoqai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
 XX PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
 XX WPI: 2001-318749/34.
 XX PT Primer sets for synthesizing polynucleotides, particularly the 5602
 PT full-length cDNAs defined in the specification, and for the detection
 PT and/or diagnosis of the abnormality of the proteins encoded by the
 XX full-length cDNAs -
 XX PS Claim 8; SEQ ID 11590; 2537pp + CD ROM; English.
 XX CC The present invention describes primer sets for synthesising 5602
 CC full-length cDNAs defined in the specification. Where a primer set

CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
 CC to the complementary strand of a polynucleotide which comprises one of
 CC the 5602 nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5'-end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3'-end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of
 CC the 5'-end sequence/3'-end sequence is selected from those defined in
 CC the specification. The primer sets can be used in antisense therapy and
 CC in gene therapy. The primers are useful for synthesising polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
 CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
 CC represent oligonucleotides, all of which are used in the exemplification
 CC of the present invention.

SQ Sequence 1087 BP; 260 A; 302 C; 306 G; 219 T; 0 other;

Query Match 60.0%; Score 20.4; DB 22; Length 1087;
 Best Local Similarity 80.0%; Pred. No. 1-2e+02;
 Matches 24; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 AGGCCTCCGAGGAGACCGCTGCCCATGCC 30
 ||||| ||| ||||| || ||||| |||||
 Db 534 AGGCCCTCCGCTGGACAGCGGTGCGCATGCC 563

RESULT 14
 AAF16239
 ID AAF16239 standard; cDNA: 1125 BP.
 XX
 AC AAF16239;
 XX
 DT 13-MAR-2001 (first entry)
 XX
 DE Human prostate cancer antigen nucleotide sequence SEQ ID NO:674.
 XX
 KW Human; prostate cancer; prostate cancer antigen; detection; diagnosis;
 KW neuroprotective; cytostatic; cardioactive; immunomodulatory; muscular;
 KW vulnary; gastrointestinal; nephrotropic; antineoplastic; gynaecological;
 KW antibacterial; gene therapy; neural; immune; reproductive; renal;
 KW gastrointestinal; pulmonary; cardiovascular; proliferative disorder;
 KW wound; infectious disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200055174-A1.
 XX
 PD 21-SEP-2000.
 XX
 PF 08-MAR-2000; 2000WG-US05988.
 XX
 PR 12-MAR-1999; 99US-0124270.
 XX

PA (HUMA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 XX
 XX Rosen CA, Ruben SM;
 XX
 XX WPI: 2000-587513/55.
 DR P-PSDB: AAB57036.
 XX

PT Prostate cancer associated gene sequences, referred to as prostate
 PT cancer antigens, useful for treatment, prevention, and diagnosis of
 PT disorders such as prostate cancer -

PS Claim 1; Page 1110; 2338pp; English.

XX

CC AAF15566 to AAF16505 encode the human prostate cancer associated
 CC proteins, called prostate cancer antigens, given in AAB56363 to AAB57302.
 CC The prostate cancer antigens can have neuroprotective, cytostatic,
 CC cardioactive, immunomodulatory, muscular, vulnary, gastrointestinal,
 CC nephrotropic, antineoplastic, gynaecological and antibacterial activities,
 CC and can be used in gene therapy. The prostate cancer antigen
 CC polynucleotides may be used for detection of prostate cancer, chromosome
 CC identification, as chromosome markers, and for numerous other diagnostic
 CC or research purposes. The prostate cancer antigens may be used to treat
 CC disorders such as neural, immune, muscular, reproductive,
 CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
 CC disorders, wounds, and infectious diseases. AAF16506 to AAF16514 to
 CC AAB57303 represent sequences used in the exemplification of the present
 CC invention.

SQ Sequence 1125 BP; 258 A; 314 C; 326 G; 222 T; 5 other;

Query Match 60.0%; Score 20.4; DB 21; Length 1125;
 Best Local Similarity 80.0%; Pred. No. 1-2e+02;
 Matches 24; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 AGGCCTCCGAGGAGACCGCTGCCCATGCC 30
 ||||| ||| ||||| || ||||| |||||
 Db 530 AGGCCCTCCGCTGGACAGCGGTGCGCATGCC 559

RESULT 15
 AAZ98235
 ID AAZ98235 standard; cDNA: 1183 BP.
 XX
 AC AAZ98235;
 XX

DT 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSP-127 cDNA SEQ ID NO:261.

XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; neurotropic; neuroprotective; cardiovascular; hepatotropic;
 KW antithumatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
 KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KW Parkinson's disease; Huntington's diseases; ovulatory defect;
 KW muscular dystrophy; ss.

XX Homo sapiens.

XX WO200000610-A2.

XX 06-JAN-2000.

XX 25-JUN-1999; 99WO-US14484.

XX 26-JUN-1998; 98US-0090762.

XX 31-JUL-1998; 98US-0094983.

XX 01-OCT-1998; 98US-0102686.

XX 11-DEC-1998; 98US-0112129.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;

PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;

XX WPI: 2000-160673/14.

XX P-PSDB: AAY87350.

XX New human signal peptide-containing proteins useful in treatment,
 PT prevention and diagnosis of e.g. cancer, inflammation and
 PT cardiovascular disease -

PS Claim 9; Page 323; 327pp; English.

XX AA298109 to AA298242 encode AAV87224 to AAV87357 which represent the
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
CC anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic,
CC neuroprotective, cardiovascular and antitumoral activities, and can
CC be used in gene therapy. HSPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSP. Antagonists of
CC HSP are used to treat or prevent disorders associated with increased
CC activity or function of HSP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
CC nucleic acids can be used for the recombinant production of HSP, for
CC detecting HSP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense,
CC triplex-forming or ribozyme therapeutics, for detecting related sequences
CC or genetic variations, and for chromosomal mapping. HSP are also used to
CC raise specific antibodies (Ab) and to screen for agonists and
CC antagonists (potential therapeutic agents). Ab are used to diagnose, or
CC monitor, HSP-related diseases (in usual immunoassays), as therapeutic
CC antagonists, in competitive drug screens, and for purification of HSP
CC from natural sources.
XX
SQ Sequence 1183 BP; 270 A; 337 C; 344 G; 232 T; 0 other;

Query Match 60.0%; Score 20.4; DB 21; Length 1183;
Best local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 24; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 AGCCCTCCGAGGACCGGTGCCCATGCC 30
 ||||| ||| ||||| ||| |||||
Db 623 AGCCCCCGCTGGAAACAGGCGTCCCATGCC 652

Search completed: March 11, 2003, 00:17:18
Job time : 159.822 secs